GHENT, Belgium, 9 January 2012 - Ablynx [Euronext Brussels:
ABLX] today announced that it will present a review of its
progress in 2011, together with an outline of the Company's
evolving strategy and a review of its portfolio and
priorities for 2012, at the 30th Annual J.P.
Morgan Healthcare Conference in San Francisco, 9-12 January
2012.
During the course of 2011, Ablynx has made significant
progress both commercially and clinically. Cash at the end of
2011 is expected to exceed EUR80M, including EUR12M of the
EUR20M upfront fee from the third co-discovery and
co-development deal with Merck Serono. During the year, four
Phase II clinical trials of Nanobody®-based products were
progressed or completed, with one achieving clinical
proof-of-concept in a disease population. Five Phase I
clinical trials were also further progressed or
completed.
During 2012, Ablynx will focus its investments on its more
advanced clinical assets, including ALX-0061 (anti-IL-6R) in
rheumatoid arthritis (RA), ALX-0081/ALX-0681 (anti-vWF) in
thrombotic thrombocytopenic purpura (TTP), ATN-103
(anti-TNF
1st Jan change | Capi. | |
---|---|---|
+23.50% | 47.07B | |
+47.87% | 42.06B | |
-5.16% | 39.98B | |
+36.37% | 33.02B | |
-7.79% | 27.9B | |
+18.06% | 27.63B | |
+47.29% | 14.37B | |
+41.91% | 13.45B | |
-1.02% | 12.03B |